ORCHID PHARMA
|
|
BOM : 524372     NSE : ORCHPHARMA     | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : NA |
Feb 17,2025 |
Price(EOD): ₹ 850.95
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 4,314.32 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
ORCHID PHARMA | -31.7% | -48.5% | -15.2% |
SUN PHARMACEUTICAL INDUSTRIES | 0.8% | -3.5% | 12.9% |
CIPLA | 1.4% | 1.9% | 2.5% |
DR REDDYS LABORATORIES | -1% | -7.9% | -4.4% |
ZYDUS LIFESCIENCES | -1.9% | -7.1% | 2.5% |
DIVIS LABORATORIES | -0.5% | -1.3% | 57.3% |
MANKIND PHARMA | -4.3% | -13.3% | 8.5% |
TORRENT PHARMACEUTICALS | -0.9% | -2.8% | 16.8% |
LUPIN | -2% | -5% | 22.6% |
FUNDAMENTAL ANALYSIS OF ORCHID PHARMA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ORCHID PHARMA
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
39.19
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 110.13 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] 3.69
P/B Calculated based on Book Value of Rs 1,169.47 Cr
[Latest Year - Mar2024 - Consolidated Results ] 4.79
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 901.55 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
-16% 7% 235% |
SHARE PRICE MOMENTUM OF ORCHID PHARMA
ORCHID PHARMA vs SENSEX
DEBT OF ORCHID PHARMA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.11 0.45 0.4 0.32 |
0.12 0.48 0.41 0.34 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF ORCHID PHARMA
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF ORCHID PHARMA
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-2.41% -13.1% -13.32% -13.32% |
-1.47% -25.5% -25.64% -25.64% |
QtrlyTrend |
-8 | |
Latest Qtr: Dec2024 | ||
Quarterly Result Analysis → |
ORCHID PHARMA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | -4.4% | -5.4% | 15% |
S&P BSE ALLCAP | -5% | -5.4% | 3.9% |
S&P BSE MIDSMALLCAP | -6.7% | -11.3% | 1.3% |
S&P BSE SMALL CAP | -7.9% | -13.7% | 0.8% |
You may also like the below Video Courses
FAQ about ORCHID PHARMA
Is ORCHID PHARMA good for long term investment?
As on Feb 17,2025, the Fundamentals of ORCHID PHARMA look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of ORCHID PHARMA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ORCHID PHARMA UnderValued or OverValued?
As on Feb 17,2025, ORCHID PHARMA is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of ORCHID PHARMA ?
As on Feb 17,2025, the Intrinsic Value of ORCHID PHARMA is Rs. 792.71 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1,017.80
Fair Value [Median EV / Sales Model] : Rs. 792.71
Fair Value [Median Price / Sales Model] : Rs. 254.28
Estimated Median Fair Value of ORCHID PHARMA : Rs. 792.71
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.